Literature DB >> 12881431

The apolipoprotein B mRNA editing complex performs a multifunctional cycle and suppresses nonsense-mediated decay.

Ann Chester1, Angelika Somasekaram, Maria Tzimina, Adam Jarmuz, Jane Gisbourne, Raymond O'Keefe, James Scott, Naveenan Navaratnam.   

Abstract

The C to U editing of apolipoprotein B (apoB) mRNA is mediated by a minimal complex composed of an RNA-binding cytidine deaminase (APOBEC1) and a complementing specificity factor (ACF). This editing generates a premature termination codon and a truncated open reading frame. We demonstrate that the APOBEC1-ACF holoenzyme mediates a multifunctional cycle. The atypical APOBEC1 nuclear localization signal is involved in RNA binding and is used to import ACF into the nucleus as cargo. APOBEC1 alone induces nonsense-mediated decay (NMD). The APOBEC1-ACF complex edits and remains associated with the edited RNA to protect it from NMD. The APOBEC1 nuclear export signal is involved in the export of ACF and the edited apoB mRNA together, to the site of translation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12881431      PMCID: PMC169042          DOI: 10.1093/emboj/cdg369

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  51 in total

Review 1.  Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic acid-binding proteins.

Authors:  E C LaCasse; Y A Lefebvre
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

Review 2.  A place in the world for RNA editing.

Authors:  J Scott
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

3.  The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.

Authors:  U Fischer; J Huber; W C Boelens; I W Mattaj; R Lührmann
Journal:  Cell       Date:  1995-08-11       Impact factor: 41.582

4.  A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme.

Authors:  S Yamanaka; K S Poksay; K S Arnold; T L Innerarity
Journal:  Genes Dev       Date:  1997-02-01       Impact factor: 11.361

5.  Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA.

Authors:  B Wolff; J J Sanglier; Y Wang
Journal:  Chem Biol       Date:  1997-02

6.  Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site.

Authors:  N Navaratnam; S Bhattacharya; T Fujino; D Patel; A L Jarmuz; J Scott
Journal:  Cell       Date:  1995-04-21       Impact factor: 41.582

Review 7.  Nucleocytoplasmic transport.

Authors:  D Görlich; I W Mattaj
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

8.  A yeast RNA-binding protein shuttles between the nucleus and the cytoplasm.

Authors:  J Flach; M Bossie; J Vogel; A Corbett; T Jinks; D A Willins; P A Silver
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase.

Authors:  N Navaratnam; J R Morrison; S Bhattacharya; D Patel; T Funahashi; F Giannoni; B B Teng; N O Davidson; J Scott
Journal:  J Biol Chem       Date:  1993-10-05       Impact factor: 5.157

10.  Apolipoprotein B mRNA editing is associated with UV crosslinking of proteins to the editing site.

Authors:  N Navaratnam; R Shah; D Patel; V Fay; J Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more
  56 in total

Review 1.  Nonsense-mediated mRNA decay: The challenge of telling right from wrong in a complex transcriptome.

Authors:  Aparna Kishor; Sarah E Fritz; J Robert Hogg
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-05-26       Impact factor: 9.957

Review 2.  Functions and regulation of the APOBEC family of proteins.

Authors:  Harold C Smith; Ryan P Bennett; Ayse Kizilyer; William M McDougall; Kimberly M Prohaska
Journal:  Semin Cell Dev Biol       Date:  2011-10-06       Impact factor: 7.727

3.  Functional characterization of APOBEC-1 complementation factor phosphorylation sites.

Authors:  David M Lehmann; Chad A Galloway; Celeste MacElrevey; Mark P Sowden; Joseph E Wedekind; Harold C Smith
Journal:  Biochim Biophys Acta       Date:  2006-12-08

4.  The cytidine deaminases AID and APOBEC-1 exhibit distinct functional properties in a novel yeast selectable system.

Authors:  Kristina Krause; Kenneth B Marcu; Jobst Greeve
Journal:  Mol Immunol       Date:  2005-06-15       Impact factor: 4.407

Review 5.  An overview of cytidine deaminases.

Authors:  Naveenan Navaratnam; Rizwan Sarwar
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

6.  Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization.

Authors:  Mark D Stenglein; Hiroshi Matsuo; Reuben S Harris
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

7.  hnRNP L-dependent protection of normal mRNAs from NMD subverts quality control in B cell lymphoma.

Authors:  Aparna Kishor; Zhiyun Ge; J Robert Hogg
Journal:  EMBO J       Date:  2018-12-07       Impact factor: 11.598

8.  Hypermutation induced by APOBEC-1 overexpression can be eliminated.

Authors:  Zhigang Chen; Thomas L Eggerman; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Gyorgy Csako; Amy P Patterson
Journal:  RNA       Date:  2010-03-26       Impact factor: 4.942

9.  RNA-editing cytidine deaminase Apobec-1 is unable to induce somatic hypermutation in mammalian cells.

Authors:  Tomonori Eto; Kazuo Kinoshita; Kiyotsugu Yoshikawa; Masamichi Muramatsu; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-14       Impact factor: 11.205

10.  Alternative splicing and extensive RNA editing of human TPH2 transcripts.

Authors:  Maik Grohmann; Paul Hammer; Maria Walther; Nils Paulmann; Andreas Büttner; Wolfgang Eisenmenger; Thomas C Baghai; Cornelius Schüle; Rainer Rupprecht; Michael Bader; Brigitta Bondy; Peter Zill; Josef Priller; Diego J Walther
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.